Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses some of the key trial data in breast cancer presented at ESMO 2022, including overall survival results from TROPiCS-02 (NCT03901339) and MONARCH 3 (NCT02246621). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.